A kind of alprazolam nasal inhalation preparation and preparation method thereof
The difficulty of administering alprazolam nasal spray in the prior art was solved by using microfluidic chips in the alprazolam nasal spray and the administration of alprazolam nasal spray and the combination of albumin and sodium alginate. The problem of low safety has achieved high blood brain barrier transmission and rapid onset, and is suitable for timely treatment of persistent epilepsy.
Patent Information
- Application Number
- CN202411329672.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-24
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-09-24
AI Technical Summary
The existing alprazolam nasal spray is easily restricted by the tight lip and teeth of patients during epilepsy during the administration of epilepsy, making it difficult to administer quickly. Since benzodiazepine drugs are difficult to dissolve in water, a large amount of cosolvent is required, resulting in The prepared nasal spray has high irritation and excessive local drug concentration, which is unfavorable to the safety of medication for patients, low blood-brain barrier transmission rate, making it difficult to effectively treat the state of persistent epilepsy.
Alprazolam gel particles are prepared by microfluidic chips, combined with Alprazolam, albumin and sodium alginate, and control the mass ratio to form gel particles with rapid and continuous release, improving blood-brain barrier permeability The particle size is controlled through microfluidic emulsification technology to ensure safety and effectiveness.
Achieved the high blood-brain barrier transmittance of alprazolam gel particles (about 70%), and quickly took effect (within 2 minutes), reducing the irritation of drug administration, improving bioavailability, and suitable for timely treatment of epilepsy The continuous state, especially the early SE, has high practical application value.
Smart Images

Figure CN118831072B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of pharmaceutical preparations, and in particular to an alprazolam nasal inhalation preparation and a preparation method thereof. Background Art
[0002] Epilepsy is one of the most common chronic neurological diseases, with more than 70 million patients worldwide. Epileptic seizures are caused by sudden abnormal, self-sustaining discharges in brain networks, usually lasting less than a few minutes. Symptoms of epileptic seizures may affect any part of the body, and are usually manifested as sudden recurrence of sensory disturbances, loss of consciousness, or convulsions. Status epilepticus (also known as status epilepticus, SE) is a severe state of epileptic seizures, which refers to a critical neurological condition in which consciousness is not fully restored during continuous epileptic seizures and recurs frequently, or seizures last for more than 30 minutes without stopping on their own. From a practical clinical perspective, a generalized convulsive seizure lasting more than 5 minutes, or a non-convulsive or partial seizure lasting more than 15 minutes, or a person whose consciousness is not fully restored during the interval between two seizures within 5 to 30 minutes, can be considered as early SE, because most seizures at this stage cannot be relieved on their own and require emergency treatment to prevent them from evolving into full status epilepticus. Current emergency treatments usually focus on intravenous / muscular infusion of higher doses of anti-epileptic drugs (even anesthetic drugs).
[0003] If prolonged epileptic seizures are not treated in time, they can cause irreversible brain damage due to high fever, circulatory failure or neuronal excitotoxic damage, with high disability and mortality rates. Because epilepsy often occurs suddenly and epilepsy itself lacks predictability, about 120,000 people die from epilepsy each year worldwide. That is to say, although clinical emergency treatment can treat status epilepticus in a targeted manner, from a practical point of view, emergency treatment is usually difficult to immediately treat patients (for example, during early SE). Benzodiazepines (such as alprazolam) have sedative, stable and muscle relaxant properties and can be used to treat status epilepticus. Chinese patent application CN110267662A discloses oral administration of alprazolam in the form of condensed aerosol. Although it can take effect relatively quickly, it is easily restricted by the patient's lips and teeth being tightly closed during an epileptic seizure, which is not conducive to the patient's own administration or the assistance of others in the administration. Chinese patent application CN1303674A discloses an alprazolam nasal spray, which is composed of the main drug alprazolam, a solvent and other pharmaceutical excipients, and according to the characteristics of nasal administration and the physicochemical properties of the drug, a solution type, a suspension type, a gel type and an emulsion type nasal inhalation preparation are prepared. Since benzodiazepines are difficult to dissolve in water, a large amount of cosolvents or even organic solvents need to be added when preparing alprazolam nasal sprays. The participation of cosolvents or organic solvents often makes the prepared nasal sprays have greater irritation. And the nasal spray is easy to cause excessive local drug concentration, which has a negative impact on the safety of patients' medication. U.S. patent application US8,895,546 discloses a pharmaceutical composition containing benzodiazepines for nasal administration, which still needs to use a large amount of organic solvents, which has a negative impact on the safety of patients' medication, and it may take 15 to 40 minutes to take effect. Summary of the invention
[0004] In a first aspect, the present invention provides an alprazolam nasal inhalation preparation, comprising alprazolam gel particles having dual properties of rapid release and sustained release, wherein the alprazolam gel particles contain at least alprazolam, albumin and sodium alginate, wherein the mass ratio of the alprazolam to the albumin is 1:(1.3-1.5), and the mass ratio of the alprazolam to the sodium alginate is 1:(0.6-1.8).
[0005] In some embodiments, the mass ratio of the alprazolam to the albumin is 1:1.3.
[0006] In some embodiments, the mass ratio of the alprazolam to the sodium alginate is 1:0.94.
[0007] The alprazolam gel microparticles provided by the present invention have both rapid release performance and sustained release performance. It should be emphasized that experiments have shown that the blood-brain barrier permeability (brain penetration rate) of the alprazolam gel microparticles provided by the present invention is about 70%. Compared with the alprazolam nasal spray (including solution type, suspension type, gel type and emulsion type) in the prior art, the blood-brain barrier permeability of the alprazolam nasal inhalation preparation provided by the present invention is significantly improved, the bioavailability is high, and it can take effect quickly (for example, within 2 minutes).
[0008] The alprazolam gel particles provided by the present invention are loaded with an appropriate amount of alprazolam on their surfaces, which can achieve rapid release of alprazolam and take effect in the early stage of administration, and can stably combine with the nasal cavity after administration, thereby continuously releasing the alprazolam inside the alprazolam gel particles, thereby achieving sustained release of alprazolam in the middle and late stages of administration.
[0009] In some embodiments, the alprazolam gel particles are prepared by a microfluidic chip, specifically comprising the following steps:
[0010] S101 adding an alprazolam solution dropwise to a first solution to form an inner phase solution; wherein the alprazolam solution comprises alprazolam, methanol and dichloromethane; the first solution is an albumin-sodium alginate aqueous solution; and the inner phase solution is an albumin-sodium alginate aqueous solution loaded with alprazolam;
[0011] S102: using the inner phase solution formed in step S101 as a dispersed phase and the second solution as a continuous phase, performing a pre-crosslinking reaction in a microfluidic chip to form preliminarily solidified pre-crosslinked droplets;
[0012] S103 collecting the pre-crosslinked droplets formed in step S102 in a third solution to perform a crosslinking reaction to form solidified particles;
[0013] S104 The solidified microparticles formed in step S103 are washed and freeze-dried to obtain the alprazolam gel microparticles.
[0014] In some embodiments, the mass ratio of the methanol to the dichloromethane in the alprazolam solution is 4:1.
[0015] In some embodiments, the concentration of alprazolam in the alprazolam solution comprises 10-15 wt %.
[0016] In some embodiments, the second solution is a calcium chloride solution, wherein the mass fraction of the calcium chloride is 0.2-1 wt %.
[0017] In some embodiments, the third solution is a calcium chloride solution, wherein the mass fraction of the calcium chloride is 2-4 wt %.
[0018] In some embodiments, the concentration of sodium alginate in the first solution is 0.9-3.0 wt %, and the concentration ratio of the albumin to the sodium alginate is 1:(0.7-1.2).
[0019] In some embodiments, the inner diameter of the channel of the microfluidic chip comprises 70 µm.
[0020] In some embodiments, the flow rate ratio of the continuous phase to the dispersed phase is 1:(5-20).
[0021] In addition, the present invention achieves the above-mentioned effect by controlling alprazolam, albumin and sodium alginate in a specific ratio. For example, when the content of alprazolam is high, although the drug loading is increased, the particle size of the alprazolam gel microparticles is not controlled, and the local concentration of alprazolam is likely to increase, and the blood-brain barrier permeability is reduced, which is not conducive to maintaining the dual performance of rapid release and sustained release. When the content of alprazolam is low, not only the drug loading is reduced, but also the particle size of the alprazolam gel microparticles is not controlled, and the blood-brain barrier permeability is reduced, which is not conducive to maintaining the dual performance of rapid release and sustained release.
[0022] In some embodiments, the alprazolam gel microparticles have a particle size of 10-50µm. Based on the microfluidic emulsification technology of the present invention (e.g., regulating the inner diameter of the channel of the microfluidic chip, the flow rate ratio of the continuous phase and the dispersed phase), the present invention can prepare alprazolam gel microparticles with uniform and controllable particle size (e.g., the particle size can be controlled to be 10-50µm). The above particle size range not only reduces the risk of gel microparticles with too small particle size being inhaled into the lungs, but also ensures the effective drug loading of the gel microparticles and the precise release of the drug, thereby ensuring the blood-brain barrier permeability and medication safety of the alprazolam nasal inhalation preparation.
[0023] In a second aspect, the present invention also provides a method for preparing an alprazolam nasal inhalation preparation, which is prepared using a microfluidic chip and comprises the following steps:
[0024] S101 adding an alprazolam solution dropwise to a first solution to form an inner phase solution; wherein the alprazolam solution comprises alprazolam, methanol and dichloromethane; the first solution is an albumin-sodium alginate aqueous solution; and the inner phase solution is an albumin-sodium alginate aqueous solution loaded with alprazolam;
[0025] S102: using the inner phase solution formed in step S101 as a dispersed phase and the second solution as a continuous phase, performing a pre-crosslinking reaction in a microfluidic chip to form preliminarily solidified pre-crosslinked droplets;
[0026] S103 collecting the pre-crosslinked droplets formed in step S102 in a third solution to perform a crosslinking reaction to form solidified particles;
[0027] S104 The solidified particles formed in step S103 are washed and freeze-dried to obtain alprazolam gel particles, and then the alprazolam nasal inhalation preparation is obtained.
[0028] In some embodiments, the mass ratio of the methanol to the dichloromethane in the alprazolam solution is 4:1.
[0029] In some embodiments, the concentration of alprazolam in the alprazolam solution comprises 10-15 wt %.
[0030] In some embodiments, the second solution is a calcium chloride solution, wherein the mass fraction of the calcium chloride is 0.2-1 wt %.
[0031] In some embodiments, the third solution is a calcium chloride solution, wherein the mass fraction of the calcium chloride is 2-4 wt %.
[0032] In some embodiments, the concentration of sodium alginate in the first solution is 0.9-3.0 wt %, and the concentration ratio of the albumin to the sodium alginate is 1:(0.7-1.2).
[0033] In some embodiments, the inner diameter of the channel of the microfluidic chip comprises 70 µm.
[0034] In some embodiments, the flow rate ratio of the continuous phase to the dispersed phase is 1:(5-20).
[0035] In some embodiments, the flow rate of the dispersed phase comprises 2-100 μL / min.
[0036] In some embodiments, the flow rate of the continuous phase comprises 10-500 μL / min.
[0037] In some embodiments, the temperature of the microfluidic chip in step S101 is controlled to be 40-45°C.
[0038] In a third aspect, the present invention also provides use of the alprazolam nasal inhalation preparation in the preparation of a drug for treating status epilepticus.
[0039] In some embodiments, the status epilepticus is an early stage of status epilepticus.
[0040] Compared with the prior art, the beneficial effects of the present invention include at least the following aspects:
[0041] Although nasal inhalation preparations theoretically have advantages such as rapid onset of drug action, the present invention has proved through experiments that existing alprazolam nasal inhalation preparations have problems such as high local alprazolam concentration and low blood-brain barrier permeability during administration, which not only makes it difficult to effectively treat patients in status epilepticus, but also introduces additional stimulation to patients, causing serious negative impact on the safety of patients' medication, and therefore is difficult to use in practice.
[0042] Compared with the prior art, the alprazolam nasal inhalation preparation provided by the present invention can achieve a blood-brain barrier permeability of 1.5-2 times that of the alprazolam nasal inhalation preparation of the prior art, has a fast onset of action (e.g., within 2 minutes), and has both rapid release and sustained release properties, and is suitable for effective and timely treatment of patients in status epilepticus (especially in the early stage of status epilepticus). The alprazolam nasal inhalation preparation provided by the present invention can be stably combined with the nasal cavity and has low irritation, thereby being able to better inhibit (or prevent) potential epileptic seizures in patients, and has high practical application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] Figure 1 The graph is a graph showing the in vitro release rate of the alprazolam nasal spray prepared in Example 1 of the present invention and Comparative Examples 1-4 as a function of release time;
[0044] Figure 2 The bar graph is a test data bar graph of the blood-brain barrier permeability of the alprazolam nasal spray prepared in Example 1 of the present invention and Comparative Examples 1-3. DETAILED DESCRIPTION
[0045] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.
[0046] Herein "and / or" includes any and all combinations of one or more of the associated listed items.
[0047] Herein, "plurality" means two or more than two, ie, it includes two, three, four, five, etc.
[0048] It should be noted that, in this article, the terms "include", "comprises" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device. In the absence of further restrictions, an element defined by the sentence "comprises a ..." does not exclude the existence of other identical elements in the process, method, article or device including the element.
[0049] As used in this specification, the term "about" typically means + / - 5% of the stated value, more typically + / - 4% of the stated value, more typically + / - 3% of the stated value, more typically + / - 2% of the stated value, even more typically + / - 1% of the stated value, even more typically + / - 0.5% of the stated value.
[0050] In this specification, some embodiments may be disclosed in a format of being in a range. It should be understood that this description of "being in a range" is only for convenience and brevity, and should not be interpreted as a rigid limitation on the disclosed range. Therefore, the description of the range should be considered to have specifically disclosed all possible sub-ranges and independent numerical values within this range. For example, the description of the range 1-6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as individual numbers within this range, such as 1, 2, 3, 4, 5 and 6. Regardless of the breadth of the range, the above rules apply.
[0051] In order to make those skilled in the art better understand the technical solution of the present invention, the present invention is further described in detail below in conjunction with specific embodiments and drawings. Unless otherwise specified, the raw materials, reagents or devices used in the following examples can be obtained from conventional commercial channels or can be obtained by existing known methods.
[0052] Example 1-5: Preparation of gel microparticle-type alprazolam nasal inhalation preparation.
[0053] The prescription is shown in Table 1 below.
[0054] Table 1. Prescriptions for the preparation of alprazolam nasal inhalation preparations in various embodiments
[0055]
[0056] Based on Table 1, the preparation was carried out as follows:
[0057] (1) dissolving alprazolam in a methanol-dichloromethane mixed solvent to obtain solution a;
[0058] (2) slowly adding solution a dropwise into the albumin-sodium alginate aqueous solution, heating the solution to 40°C, and then cooling the solution to obtain the albumin-sodium alginate aqueous solution loaded with alprazolam, i.e., the inner phase b;
[0059] (3) Using a microfluidic method, the internal phase b is used as the dispersed phase and the aqueous solution containing calcium chloride is used as the continuous phase. A pre-crosslinking reaction occurs in the microfluidic chip, and the continuous phase shears and preliminarily solidifies the internal phase b to obtain preliminarily solidified pre-crosslinked droplets;
[0060] (4) collecting the pre-crosslinked liquid in a collection phase to undergo a crosslinking reaction, and further curing to obtain cured particles;
[0061] (5) Washing the solidified particles with pure water by suction filtration;
[0062] (6) vacuum freeze-drying the washed particles to obtain alprazolam gel particles;
[0063] (7) Determine the content of the prepared alprazolam gel microparticles, fill, seal, and install a particle spray pump to obtain a gel microparticle-type alprazolam nasal inhalation preparation.
[0064] After testing, the particle size and drug loading data of the alprazolam gel microparticles prepared in Examples 1 to 5 are shown in Table 2 below.
[0065] Table 2. Technical parameters of microfluidics and particle size and drug loading data of alprazolam gel microparticles of Examples 1-5
[0066]
[0067] As can be seen from Table 2 above, when the mass ratio of alprazolam to albumin is within the range of 1:(1.3-1.5), alprazolam gel microparticles with a particle size of 10-50µm can be prepared more stably, and the drug loading is 25.41%-28.9%, which is suitable for the preparation of alprazolam nasal inhalation preparations. When the mass ratio of alprazolam to albumin is greater than 1:1.5, not only the drug loading of alprazolam gel microparticles is reduced, but also the particle size of the obtained gel microparticles is less than 10µm, which is prone to the risk of inhalation into the lungs and the release performance is unstable. When the mass ratio of alprazolam to albumin is less than 1:1.3, the particle size of the obtained alprazolam gel microparticles is greater than 50 µm, and compared with the 10-50µm gel microparticles, the release performance is unstable, which affects the therapeutic effect of SE.
[0068] Comparative Example 1: Preparation of solution-type alprazolam nasal spray
[0069] See the nasal spray prepared in Example 1 disclosed in patent CN1303674A.
[0070] Comparative Example 2: Preparation of gel-type alprazolam nasal spray
[0071] See the nasal spray prepared in Example 5 disclosed in patent CN1303674A.
[0072] Comparative Example 3: Preparation of suspension type alprazolam nasal spray
[0073] See the nasal spray prepared in Example 6 disclosed in patent CN1303674A.
[0074] Comparative Example 4: Preparation of emulsion type alprazolam nasal spray
[0075] See the nasal spray prepared in Example 12 disclosed in patent CN1303674A.
[0076] The nasal sprays of Example 1 and Comparative Examples 1-4 were tested for in vitro release (IVTR) respectively. The experimental method was based on the "Expert Consensus on Technical Specifications for In Vitro Release Tests of Semisolid Preparations for Skin and Mucous Membranes" (Chinese Modern Applied Pharmacy, Vol. 39, No. 20, October 2022), using a three-dimensional diffusion cell model. The test results are shown in Figure 1 .
[0077] from Figure 1 It can be seen that the nasal sprays of comparative examples 1-4 can be released quickly at the initial stage of administration (e.g., within 1 h). On the one hand, this will result in an excessively high local concentration of alprazolam; on the other hand, in practical applications, this will result in the release of alprazolam being terminated at the initial stage of administration. When faced with patients with status epilepticus that is difficult to control, the nasal sprays of comparative examples 1-4 are often difficult to control continued epileptic seizures. In other words, the nasal sprays of comparative examples 1-4 may need to be administered repeatedly. However, since alprazolam is a prescription drug, it is difficult for epileptic patients to carry multiple doses of nasal sprays such as those of comparative examples 1-4, which increases the risk of status epilepticus being difficult to control and limits the time for patients to seek medical treatment. The alprazolam nasal inhalation preparation of Example 1 of the present invention can be released quickly at the initial stage of administration, achieving the purpose of rapid onset of action while also having a certain effect of controlling local concentration, reducing irritation to patients (especially to the nasal cavity).
[0078] Combination Figure 2It can be seen from the blood-brain barrier permeability that the 1-hour blood-brain barrier permeability of the alprazolam nasal inhalation preparation of Example 1 of the present invention is significantly higher than that of Comparative Examples 1-3, which indicates that the alprazolam nasal inhalation preparation provided by the present invention significantly improves the blood-brain barrier permeability of the alprazolam drug, and can achieve efficient and rapid release within 1 hour. Compared with the nasal spray of Comparative Examples 1-3, in the middle and late stages of administration, the alprazolam nasal inhalation preparation of Example 1 of the present invention has a better sustained-release effect, and can achieve continuous slow release within 24 hours. The effect of controlling status epilepticus is sufficient to persist until the epileptic patient is sent to the doctor for treatment, without the need for repeated administration, and is particularly suitable for situations where the patient does not have sufficient time to be sent to the doctor for treatment. In addition, the alprazolam nasal inhalation preparation provided by the present invention can also avoid the stimulation caused by repeated administration of Comparative Examples 1-4, thereby reducing the clearance effect of cilia on alprazolam.
[0079] The method for detecting the blood-brain barrier permeability is as follows: rats are given 10 µg of the nasal spray of Example 1 and Comparative Examples 1-3, respectively, and plasma and brain tissue samples are collected one hour later. After the sample is pre-treated, the supernatant is extracted, and the concentration of alprazolam is detected by LC-MS, and the ratio of the brain tissue concentration to the plasma concentration is the blood-brain barrier permeability. The chromatographic conditions of the detection method are: chromatographic column ACQUITY UPLC HSS T3 (100*2.1mm, 1.8μm), temperature setting 40°C, mobile phase 0.1% formic acid aqueous solution (aqueous phase) and 0.1% formic acid acetonitrile (organic phase), flow rate 0.3ml / min, run for 7 minutes. The mass spectrometry conditions are MRM=309.2 / 281.2.
[0080] The embodiments of the present invention are described above in conjunction with the accompanying drawings, but the present invention is not limited to the above-mentioned specific implementation modes, which are merely illustrative rather than restrictive. Under the guidance of the present invention, ordinary technicians in this field can also make many forms without departing from the scope of protection of the present invention and the claims, all of which are within the protection of the present invention.
Claims
1. An alprazolam nasal inhalation preparation, characterized in that: The nasal inhalation preparation comprises alprazolam gel particles with dual properties of rapid release and sustained release, wherein the alprazolam gel particles at least contain alprazolam, albumin and sodium alginate, wherein the mass ratio of alprazolam to the albumin is 1:1.3-1.5, and the mass ratio of alprazolam to the sodium alginate is 1:0.6-1.8; the alprazolam gel particles are prepared by the following steps: S101 adding an alprazolam solution dropwise to the first solution to form an internal phase solution, wherein the alprazolam solution comprises alprazolam, methanol and dichloromethane; The first solution is an albumin-sodium alginate aqueous solution; the internal phase solution is an albumin-sodium alginate aqueous solution loaded with alprazolam; the concentration of alprazolam in the alprazolam solution is 10-15wt%; the concentration of sodium alginate in the first solution is 0.9-3.0wt%, and the concentration ratio of the albumin to the sodium alginate is 1:0.7-1.2; S102: using the inner phase solution formed in step S101 as a dispersed phase and the second solution as a continuous phase, performing a pre-crosslinking reaction in a microfluidic chip to form preliminarily solidified pre-crosslinked droplets; S103 collecting the pre-crosslinked droplets formed in step S102 in a third solution to perform a crosslinking reaction to form solidified particles; S104 washing and freeze-drying the solidified particles formed in step S103 to obtain the alprazolam gel particles; The second solution is a calcium chloride solution, wherein the mass fraction of the calcium chloride is 0.2-1wt%; the third solution is a calcium chloride solution, wherein the mass fraction of the calcium chloride is 2-4wt%.
2. The alprazolam nasal inhalation preparation according to claim 1, characterized in that: The particle size of the alprazolam gel microparticles is 10-50 μm.
3. The alprazolam nasal inhalation preparation according to claim 1, characterized in that: The flow rate ratio of the continuous phase to the dispersed phase is 1:5-20.
4. A method for preparing the alprazolam nasal inhalation preparation according to any one of claims 1 to 3, characterized in that: The microfluidic chip is prepared, including the following steps: S101 adding an alprazolam solution dropwise to the first solution to form an inner phase solution; wherein the alprazolam solution comprises alprazolam, methanol and dichloromethane; the first solution is an albumin-sodium alginate aqueous solution; the inner phase solution is an albumin-sodium alginate aqueous solution loaded with alprazolam; the concentration of alprazolam in the alprazolam solution is 10-15wt%; the concentration of sodium alginate in the first solution is 0.9-3.0 wt%, and the concentration ratio of albumin to sodium alginate is 1:0.7-1.2; S102: using the inner phase solution formed in step S101 as a dispersed phase and the second solution as a continuous phase, performing a pre-crosslinking reaction in a microfluidic chip to form preliminarily solidified pre-crosslinked droplets; S103 collecting the pre-crosslinked droplets formed in step S102 in a third solution to perform a crosslinking reaction to form solidified particles; S104 washing and freeze-drying the solidified particles formed in step S103 to obtain alprazolam gel particles, and then obtaining the alprazolam nasal inhalation preparation; The second solution is a calcium chloride solution, wherein the mass fraction of the calcium chloride is 0.2-1wt%; the third solution is a calcium chloride solution, wherein the mass fraction of the calcium chloride is 2-4wt%.
5. The preparation method according to claim 4, characterized in that: The mass ratio of the methanol to the dichloromethane in the alprazolam solution is 4:
1.
6. The preparation method according to claim 4, characterized in that: The particle size of the alprazolam gel microparticles is 10-50 μm.
7. The preparation method according to claim 4, characterized in that: The flow rate of the dispersed phase is 2-100 μL / min.
8. The preparation method according to claim 4, characterized in that: The inner diameter of the channel of the microfluidic chip is 70 μm.
9. The preparation method according to claim 4, characterized in that: The flow rate ratio of the continuous phase to the dispersed phase is 1:5-20.
10. The preparation method according to claim 4, characterized in that: In step S101, the temperature of the microfluidic chip is controlled to be 40-45°C.
Citation Information
Patent Citations
Method of treating epilepsy
CN110267662A
Alprazolam nasal spray
CN1303674A
Administration of benzodiazepine compositions
US8895546B2
Oridonin porous particle inhalant and application thereof on treating primary lung cancer
CN105919984A
Methods of treating epilepsy
CN116172985A
